Purpose of Review <p>This review aims to provide an updated, comparative overview of endemic mycoses affecting pediatric populations: paracoccidioidomycosis, talaromycosis, and sporotrichosis. It seeks to address gaps in clinical recognition, diagnosis, treatment strategies, and outcomes in children, with a focus on geographic and immunological risk factors.</p> Recent Findings <p>Recent studies have highlighted shifts in the epidemiology of these infections due to environmental and demographic changes. Advances include improved molecular diagnostics such as PCR and metagenomic sequencing, safer antifungal therapies like amphotericin B colloidal dispersion, and novel approaches such as nanotechnology for PCM treatment. New data from large pediatric cohorts underscore the burden of these diseases and variations in clinical presentation and to explore prevention strategies like immunization.</p> Summary <p>Early diagnosis and targeted antifungal therapy are critical to favorable outcomes in pediatric endemic mycoses. Continued research is essential to improve access to rapid diagnostics and safe treatments, especially in resource-limited endemic regions.</p>